Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Loading...
Most Recent Stories

Grantham’s Prudent Investor Portfolio

I found this section of GMO’s latest quarterly letter to be of particular interest.  Grantham discusses a “prudent investor” portfolio that can provide decent risk adjusted returns in a tough environment:

“Exhibit 1 shows an example of a portfolio that might be used in a world that excludes private equity and venture capital, and for a client who can do without a benchmark and can settle for owning a (hopefully) sensible long-term efficient portfolio.  Efficient, that is, in terms of trying to minimize risk per unit of estimated returns. As always, and particularly in this type of overpriced environment, there are no guarantees of success even if every GMO recommendation were to be implemented for, regrettably, we too are often imperfect.”

GMO

Hard to say what all of that amounts to precisely, but it’s logical that “alternative” could be option based strategies since Ben Inker spent quite a bit of time earlier in the note discussing those approaches.  Cash plus is just utilizing cash like a call option in all likelihood.  It’s impossible to properly judge a portfolio like this because we don’t know the actual components, but my guess is that it would perform a lot like a 60/40 with lower returns and slightly lower risks.  But that’s just a guess.  Anyhow, lots of good moving parts there to think about.  Read the full letter here.